Comparison of Quantitation of Cytomegalovirus DNA by Real-Time PCR in Whole Blood with the Cytomegalovirus Antigenemia Assay
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Quantitation of cytomegalovirus (CMV) DNA using real-time PCR has been utilized for monitoring CMV infection. However, the CMV antigenemia assay is still the ‘gold standard’ assay. There are only a few studies in Korea that compared the efficacy of use of real-time PCR for quantitation of CMV DNA in whole blood with the antigenemia assay, and most of these studies have been limited to transplant recipients. Method: 479 whole blood samples from 79 patients, falling under different disease groups, were tested by real-time CMV DNA PCR using the Q-CMV real-time complete kit (Nanogen Advanced Diagnostic S.r.L., Italy) and CMV antigenemia assay (CINA Kit, ArgeneBiosoft, France), and the results were compared. Repeatedly tested patients were selected and their charts were reviewed for ganciclovir therapy. Results: The concordance rate of the two assays was 86.4% (Cohen’s kappa coefficient value=0.659). Quantitative correlation between the two assays was a moderate (r=0.5504, P<0.0001). Among 20 patients tested repeatedly with the two assays, 13 patients were transplant recipients and treated with ganciclovir. Before treatment, CMV was detected earlier by real-time CMV DNA PCR than the antigenemia assay, with a median difference of 8 days. After treatment, the antigenemia assay achieved negative results earlier than real-time CMV DNA PCR with a median difference of 10.5 days. Conclusions: Q-CMV real-time complete kit is a useful tool for early detection of CMV infection in whole blood samples in transplant recipients.
Abstract
Background: Quantitation of cytomegalovirus (CMV) DNA using real-time PCR has been utilized for monitoring CMV infection. However, the CMV antigenemia assay is still the ‘gold standard’ assay. There are only a few studies in Korea that compared the efficacy of use of real-time PCR for quantitation of CMV DNA in whole blood with the antigenemia assay, and most of these studies have been limited to transplant recipients. Method: 479 whole blood samples from 79 patients, falling under different disease groups, were tested by real-time CMV DNA PCR using the Q-CMV real-time complete kit (Nanogen Advanced Diagnostic S.r.L., Italy) and CMV antigenemia assay (CINA Kit, ArgeneBiosoft, France), and the results were compared. Repeatedly tested patients were selected and their charts were reviewed for ganciclovir therapy. Results: The concordance rate of the two assays was 86.4% (Cohen’s kappa coefficient value=0.659). Quantitative correlation between the two assays was a moderate (r=0.5504, P<0.0001). Among 20 patients tested repeatedly with the two assays, 13 patients were transplant recipients and treated with ganciclovir. Before treatment, CMV was detected earlier by real-time CMV DNA PCR than the antigenemia assay, with a median difference of 8 days. After treatment, the antigenemia assay achieved negative results earlier than real-time CMV DNA PCR with a median difference of 10.5 days. Conclusions: Q-CMV real-time complete kit is a useful tool for early detection of CMV infection in whole blood samples in transplant recipients.
참고문헌 (23)
- Paya CV, "Prevention of cytomegalovirus disease in recipients of solid-organ transplants", Clin Infect Dis, 32, pp.596~603 (2001)
- Boeckh M, "Quantitation of cytomegalovirus: methodologic aspects and clinical applications", Clin Microbiol Rev, 11, pp.533~554 (1998)
- Allice T, "Evaluation of a novel real-time PCR system for cytomegalovirus DNA quantitation on whole blood and correlation with pp65-antigen test in guiding pre-emptive antiviral treatment", J Virol Methods, 148, pp.9~16 (2008)
- Guiver M, "Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients", Transplantation, 71, pp.1609~1615 (2001)
- Camargo LF, "Comparison between antigenemia and a quantitative-competitive polymerase chain reaction for the diagnosis of cytomegalovirus infection after heart transplantation", Transplantation, 71, pp.412~417 (2001)
- Heid CA, "Realtime quantitative PCR", Genome Res, 6, pp.986~994 (1996)
- 최수미, "Comparison of Quantitative Cytomegalovirus Real-time PCR in Whole Blood and pp65 Antigenemia Assay: Clinical Utility of CMV Real-time PCR in Hematopoietic Stem Cell Transplant Recipients", Journal of Korean Medical Science, 24(4), pp.571~578 (2009), 대한의학회
- Marchetti S, "Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants", New Microbiol, 34, pp.157~164 (2011)
- Ljungman P, "Definitions of cytomegalovirus infection and disease in transplant recipients", Clin Infect Dis, 34, pp.1094~1097 (2002)
- Paya CV, "Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial", J Infect Dis, 185, pp.854~860 (2002)
- Kotton CN, "Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation", Transplantation, 96, pp.333~360 (2013)
- Griffiths PD, "The challenge of CMV infection and disease in transplantation", Recommendations from the International Herpes Management Forum (IHMF) Managements Strategies Workshop and 8th Annual Meeting of the IHMF (2000), Cambridge Medical Publications
- Lilleri D, "Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients", J Med Virol, 73, pp.412~418 (2004)
- Razonable RR, "The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease", Transplantation, 73, pp.968~973 (2002)
- Von Müller L, "High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay", J Clin Microbiol, 40, pp.2285~2287 (2002)
- 허운보, "거대세포바이러스 정량 검출을 위한 BiosewoomTM Real-Q CytomegalovirusQuantification kit 평가", Annals of Laboratory Medicine, 27(4), pp.298~304 (2007), 대한진단검사의학회
- Li H, "Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients", J Clin Microbiol, 41, pp.187~191 (2003)
- Kalpoe JS, "Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection", J Clin Microbiol, 42, pp.1498~1504 (2004)
- Mhiri L, "Comparison of pp65 antigenemia, quantitative PCR and DNA hybrid capture for detection of cytomegalovirus in transplant recipients and AIDS patients", J Virol Methods, 143, pp.23~28 (2007)
- Ghaffari SH, "Monitoring of cytomegalovirus reactivation in bone marrow transplant recipients by real-time PCR", Pathol Oncol Res, 14, pp.399~409 (2008)
- Pillet S, "Quantification of cytomegalovirus viral load", Expert Rev Anti Infect Ther, 12, pp.193~210 (2014)
- Kim DJ, "Real-time PCR assay compared with antigenemia assay for detecting cytomegalovirus infection in kidney transplant recipients", Transplant Proc, 39, pp.1458~1460 (2007)
- Rhee JY, "Clinical usefulness of plasma quantitative polymerase chain reaction assay: diagnosis of cytomegalovirus infection in kidney transplant recipients", Transplant Proc, 43, pp.2624~2629 (2011)